CLDX SVP & General Counsel Freddy Jimenez Buys 93,000 Shares

Executive Freddy Jimenez Buys Celldex Shares

Celldex Therapeutics, Inc. (NasdaqCM: CLDX) saw its senior vice president and general counsel, Freddy Jimenez, acquire 93,000 shares on June 25, 2026. This purchase occurred during a broad wave of insider buying across the biopharmaceutical firm, reflecting active leadership engagement as the company advances its clinical pipeline.

Celldex Stock Sits in Middle of Yearly Range

The stock changes hands around $35.26, placing it comfortably above its 200-day moving average of $32.18, though beneath its 50-day moving average of $39.10. Over the past year, the equity has moved between a 52-week low of $22.10 and a peak of $45.14. Market watchers follow these trading bands closely as the firm prepares for its next scheduled financial update on November 9, 2026.

Broad Wave of Insider Purchases

The June 25 transaction was shared with multiple other leaders at the firm. CEO Anthony Marucci led the group by acquiring 375,000 shares, while executive vice president and chief scientific officer Tibor Keler picked up 115,000 shares. Additional buying came from Sarah Cavanaugh and Margo Heath-Chiozzi, who bought 95,000 shares each. Board members Harry Penner Jr. and Conrad Herbert also joined the push, purchasing 26,000 shares each on that same date.

Wall Street Analyst Forecasts and Price Targets

Analyst coverage for the healthcare company remains active, featuring several recent target adjustments. On October 2, 2026, HC Wainwright & Co. reiterated a buy rating with a $64.00 price target. Earlier in September, Leerink Partners raised its target to $88.00 while maintaining an outperform rating, and Morgan Stanley lifted its target to $57.00 with an overweight rating. Cantor Fitzgerald also maintained an overweight rating on September 22 with a $72.00 target. Across the broader community, the stock holds a consensus strong buy recommendation backed by 14 analyst opinions.

Inside the Biotechnology Pipeline

Headquartered in Hampton, New Jersey, Celldex Therapeutics works on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune conditions. Its clinical candidates target mast cell-mediated diseases where existing treatments fall short. Key programs include Barzolvolimab, designed to bind the KIT receptor for treating chronic urticarias, prurigo nodularis, and atopic dermatitis, alongside bispecific candidates addressing complex inflammatory pathways.

Upcoming Financial and Reporting Dates

Market participants will look toward the company's next earnings report on November 9, 2026, for further updates on financial performance and clinical milestones. Insider transactions offer a look at how leaders view their enterprise, though they do not guarantee future stock movements.